Materials and methods: miRNA microarray was performed to identify the differentially abundant miRNAs in the serums of systemic lupus erythematosus (SLE) patients with steroid-induced ONFH as compared with SLE control and healthy control group.
We predicted the potential functions of these differentially abundant miRNAs using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses and reconstructed the regulatory networks of miRNA-mRNA interactions.
Results: Our data indicated that there were 11 differentially abundant miRNAs (2 upregulated and 9 downregulated) between SLE-ONFH group and healthy control group and 42 differentially abundant miRNAs (14 upregulated and 28 downregulated) between SLE-ONFH group and SLE control group. We also predicted the potential functions of these differentially abundant miRNAs using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses and reconstructed the regulatory networks of miRNA-mRNA interactions.
Conclusions:
These findings corroborated the idea that circulating miRNAs play significant roles in the development of ONFH and may serve as diagnostic markers and therapeutic targets.
conserved and their expression is tissue-specific. 19, 20 They play vital roles in different physiological and pathological processes via regulating gene expression post-transcriptionally. [21] [22] [23] Aberrant expression of miRNAs has been documented in the different orthopaedic conditions, such as intervertebral disc degeneration, osteoarthritis, osteoporosis and osteosarcoma. [24] [25] [26] [27] Several recent studies also suggested that miRNAs might take part in the development of ONFH. [28] [29] [30] To date, alterations in circulating miRNAs in steroid-associated ONFH remain largely unknown.
In this study, we profiled differentially abundant miRNAs in serums of systemic lupus erythematosus (SLE) patients with steroidassociated ONFH as compared with SLE and healthy controls. We further inferred the potential functions of these differentially abundant miRNAs by Gene Ontology (GO) and Kyoto Encyclopedia of 
| MATERIALS AND METHODS

| Serum collection
Blood samples were collected from 3 patients with ONFH secondary to application of corticosteroids for the treatment of SLE. Three SLE patients that underwent similar corticosteroid treatment but without ONFH together with 3 matched healthy subjects were used as controls. Subject information is provided in 
| RNA extraction
Total RNA from the serum was extracted using the MiRNeasy Mini kit (217004; Qiagen, Hilden, Germany) according to the manufacturers' instructions. Total RNA was dissolved in 300 μL elution buffers and measured by the NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA). The total RNA was concentrated following centrifugation.
| MicroRNA microarray
Affymetrix microRNA 4.0 array was performed to analyse serum microRNAs according to the manufacturer's instructions. For each sample, a total of 100 ng of RNA was dephosphorylated, the 3′-end labelled with the Cy3-pCp, purified, dried and hybridized to the array.
Average values of the replicate spots of each miRNA were background subtracted, normalized and subject to further analysis. The expressed result was normalized by using median normalization assay, after which differentially expressed miRNA was identified through the volcano plot filtering. Hierarchical clustering was performed by using MEV software. Normalization was performed using the signal of U6 small nuclear RNA on the chip. 
| KEGG pathway and Go annotation analyses
| Analysis of miRNA regulatory network
To delineate the role and interactions among miRNAs and mRNAs in steroid-associated ONFH pathogenesis, we constructed a miRNA regulatory network. The interaction network was established and visually displayed using the Cytoscape software. miRNA-mRNA interactions were predicted with the miRNA and PsRobot software.
| Statistical analysis
Results were presented as the mean ± SD (standard deviation). The difference between 2 groups was analysed by Student's t test. Oneway or two-way analysis of variance (ANOVA) was performed to measure the significant difference between 3 or more groups. P < .05 was considered to be statistically significant. 
| Differentially abundant miRNAs in serums of SLE-ONFH patients
To investigate if circulating miRNAs could be used to differentiate steroid-associated SLE-ONFH patients from SLE and healthy controls, microRNA microarray was performed. We analysed differentially abundant miRNAs by the significance analysis of microarrays (SAM) method with the Cuffdiff software following the criteria of q < 0.05. Differentially abundant miRNAs between different groups were visualized using heatmap and Volcano plot. Serum miRNAs with increased or decreased levels in the SLE-ONFH group compared with SLE or healthy controls are listed in Tables 1-3 , respectively. All differentially abundant miRNAs are shown in Figure 1A as a heatmap. Figure 1B shows the heatmap of differentially abundant miRNAs between the SLE-ONFH group and healthy control group, while Figure 1C shows the heatmap of differentially abundant miRNAs between SLE-ONFH group and the SLE control group. The heatmap of differentially abundant miRNAs between the SLE and healthy control groups was shown in Figure 1D . Figure 2 shows volcano plots, which F I G U R E 3 Functional predictions of differentially abundant miRNAs in SLE-ONFH vs healthy control. A-C, Molecular functions, biological processes and cellular components were predicted to be altered by mRNAs targeted by differentially abundant miRNAs in ONFH. Directed Acyclic Graph (DAG) is the graphical display of GO enrichment results with candidate target genes. D, The number of genes in GO term was shown in histograph. E-G, Enriched biological processes, cellular components and molecular functions in ONFH were shown. H, Scatterplot of enriched KEGG pathway showing statistics of pathway enrichment in ONFH depict significance vs fold change on the y-and x-axes, respectively, of differentially abundant miRNAs between groups. Details of differentially abundant miRNAs are as follows: 11 differentially abundant miRNAs (2 upregulated and 9 downregulated), 42 differentially abundant miRNAs (14 upregulated and 28 downregulated) and 9 differentially abundant miRNAs (1 upregulated and 8 downregulated) between SLE-ONFH group and healthy control group, SLE-ONFH group and SLE control group, and SLE control group and healthy control group, respectively. In particular, we observed consistent increased levels ofmiR-4440 and decreased levels of 6 miRNAs, namely miR-6787-5p, 6717-5p, miR-500a-3p, miR-130a-3p, miR-3663-3p and miR-222-3p, in SLE-ONFH patients as compared with both control groups. and SLE control group and healthy control group ( Figure 5H ).
F I G U R E 4 Functional predictions of differentially abundant miRNAs in SLE-
In particular, hypertrophic cardiomyopathy was significantly enriched in the SLE-ONFH groups as compared with both control groups, suggesting that hypertrophic cardiomyopathy and steroid-associated ONFN might share an overlapped molecular pathogenic pathway.
F I G U R E 6 Regulatory networks of miRNAs and mRNAs between SLE-ONFH group and healthy control group
| Regulatory network of miRNAs and mRNAs
To analyse the molecular mechanism of the differentially abundant miRNAs in ONFH pathogenesis, we constructed the regulatory network of the involved miRNAs and the predicted target mRNAs. Figure 6 shows miRNA-mRNA regulatory network, involving deregulated (down/up) miRNAs and their deregulated target genes (fold change: >2.0; P ≤ .05)
between SLE-ONFH group and healthy control group. Figures 7 and 8 show miRNA-mRNA regulatory network, involving deregulated (down/ up) miRNAs and their deregulated target genes (fold change: >2.0; P ≤ .05) between SLE-ONFH group and SLE control group and between SLE control group and healthy control group, respectively. These data explained the regulatory relationship between miRNA and mRNA in the pathogenesis of steroid-associated ONFH.
| DISCUSSION
Multiple lines of evidences have suggested that miRNAs could play active and crucial roles in the development of ONFH. 8, [31] [32] [33] [34] In this study, we performed miRNA microarray to identify the differentially abundant miRNAs in the serums of SLE patients with steroidinduced ONFH as compared with SLE control and healthy control groups. Our data indicated that miR-4440 was commonly increased,
Regulatory networks of miRNAs and mRNAs between SLE-ONFH group and the SLE control group while miR-6787-5p, 6717-5p, miR-500a-3p, miR-130a-3p, miR-3663-3p and miR-222-3p were consistently decreased in SLE-ONFH patients as compared with both control groups. We also predicted the potential functions of differentially abundant miR- volunteers. There were 3 miRNAs downregulated and 9 miRNAs upregulated in the hormone non-traumatic ONFH group compared with healthy control. Our previous study also showed that there were 27 miRNAs deregulated in the steroid-induced ONFH patients. Some miRNAs were involved in the modulation of cell differentiation, proliferation and apoptosis of stem cells. However, miRNAs deregulated in these studies were not consistent.
In this study, we found that there were 11 differentially abundant miRNAs (2 upregulated, miR-4440 and miR-6813-5p; and 9 downregulated: miR-6787-5p, miR-606, miR-22-3p, miR-6717-5p, miR500a-3p, miR-130a-3p, miR-3663-3p, miR-222-3p and miR-324-3p)
between ONFH group and healthy control group. Forty-two differentially abundant miRNAs (14 upregulated and 28 downregulated) were found between ONFH group and SLE control group. These microarray results offered a starting point for explaining the potential roles of miRNAs in the ONFH. Among these differentially abundant miRNAs identified in study, the consistently deregulated miRNAs, namely miR-4440, miR-6787-5p, 6717-5p, miR-500a-3p, miR-130a-3p, in bone remodelling and homeostasis [43] . However, the function and mechanisms of miRNAs as predicted by KEGG and GO analyses should be experimentally verified and studied in-depth in the future work. The molecular mechanism underlying the interaction of miRNAs and mRNAs in ONFH remains largely unclear. Therefore, for the first time, the miRNA-mRNA network of ONFH was reconstructed based on our second sequencing data. These pioneering discoveries might enrich our understanding on the mechanisms underlying the role of miRNAs in ONFH pathogenesis.
In conclusion, our study indicated that several miRNAs were differentially abundant in the serums of steroid-induced ONFH with SLE, as compared with SLE patients without ONFH and healthy subjects. Our bioinformatic analyses also predicted the signalling pathways and target genes of these miRNAs, which may provide potential understanding of the involvement of miRNAs in the initiation and development of ONFH. These data may provide new targets for the early diagnosis and treatment of ONFH. However, large-scale validation studies in different populations are still required to fully realize the potential of circulating miRNAs as diagnostic markers for ONFH.
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